CLAIMS

1.- Peptides that are antagonists of the binding of TGFβ1 to its receptors in the body, characterized by being synthetic peptides with sequences having ≤ 15 amino acids that are identical or similar to those of natural TGFβ1 and/or its receptors.

2.- Active peptide according to Claim 1, characterized in that it has the amino acid sequence SEQ ID NO: 3.

3.- Active peptide according to Claim 1, characterized in that it has the amino acid sequence SEQ ID NO: 4.

4.- Active peptide according to Claim 1, characterized in that it has the amino acid sequence SEQ ID NO: 5.

5.- Active peptide according to Claim 1, characterized in that it has the amino acid sequence SEQ ID NO: 6.

6.- Active peptide according to Claim 1, characterized in that it has the amino acid sequence SEQ ID NO: 7.

7.- Active peptide according to Claim 1, characterized in that it has the amino acid sequence SEQ ID NO: 8.

8.- Active peptide according to Claim 1, characterized in that it has the amino acid sequence SEQ ID NO: 9.

9.- Mimotopes of any of the active peptides of Claims 1 to 8, characterized in that they display an antagonistic effect similar to them, but a longer average life in the body than the latter.

10.- Method of using at least one of the active peptides of Claims 1 to 8 and/or at least one of their mimotopes for manufacturing a composition for application in liver diseases.

11.- Method of using at least one DNA that codes for at least one of the active peptides of Claims 1 to 8 for manufacturing a composition for application in liver

diseases that optionally includes at least one of the mimotopes of the said active peptides.

12.- Method of using at least one recombinant expression system that codes for at least one of the active peptides of Claims 1 to 8 for manufacturing a composition for application in liver diseases that optionally includes at least one of the mimotopes of the said active peptides.

13.- Method according to Claim 12, characterized in that the recombinant system is a defective adenovirus.

14.- Method according to Claim 12, characterized in that the recombinant system is a plasmid.

15.- Method according to Claims 11 to 14 for application to hepatic fibrosis.

REPLACEMENT SHEET